Electronic Supplementary Material (ESI) for ChemComm. This journal is © The Royal Society of Chemistry 2019

Supporting Information

Pd-Catalyzed Asymmetric Allylic Substitution Cascade via An Asymmetric Desymmetrization for the Synthesis of Bicyclic

Dihydrofurans

Kai Xu,^a Hao Liu,^a Yilin Hou,^a Jiefeng Shen,^{*,a} Delong Liu^{*,a} and Wanbin Zhang^{a,b}

^aShanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Pharmacy, ^bSchool of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, P. R. China

Contents

1. General Details	S1
2. Preparation of 3-Oxo-nitrile Substrates	S1
3. General Procedure for the Preparation of Allyl Biscarbonates	S6
4. General Procedure for the Pd-Catalyzed Asymmetric Allylic Substitution	S8
5. Transformations	
6. NMR Spectra	
7. HPLC Data	
8. X-ray Crystal Structure Analysis	S110
9. References	S112

1. General Details

The NMR spectra were recorded on Bruker Advance III HD 400 (400 MHz, ¹H; 100 MHz, ¹³C) or Bruker Advance III HD 500 (500 MHz, ¹H; 125 MHz, ¹³C) and dealed with the software MestReNova. HRMS was performed on a Waters Micromass Q-TOF Premier Mass Spectrometer at the Instrumental Analysis Center of Shanghai Jiao Tong University. Melting points were measured with SGW X-4 micro melting point apparatus. X-Ray crystallography data were collected using an Xcalibur Atlas Gemini ultra diffractometer. Enantioselectivity was measured by high performance liquid chromatography (HPLC) using Daicel Chiralcel OD-H, AS-H, IC-3 and OJ-H columns with *n*-hexane/*i*-PrOH as an eluent. Column chromatography was performed using 100–200 mesh silica gel. The commercially available reagents were used without further purification.

2. Preparation of 3-Oxo-nitrile Substrates

General Procedure A: To a solution of ester (10 mmol, 1.0 equiv) in THF (20 mL) under a nitrogen atmosphere was added NaH (15 mmol, 60 % dispersion in mineral oil, 1.5 equiv) at r.t and the mixture was stirred for 30 min. Acetonitrile (20 mL) was added dropwise and the reaction mixture was stirred at 60 °C for 12 h. The reaction was quenched with H₂O and the solvent was removed in vacuo. The water phase was extracted with ethyl acetate (3×25 mL). The combined organic phase was dried over anhydrous Na₂SO₄ and then concentrated in vacuo. The residue was purified by column chromatography on silica gel (petroleum ether : ethyl acetate = 3:1) to obtain the corresponding 3-oxo-3-propanenitrile.

General Procedure B: To a solution of *n*-BuLi (25 mmol, 2.5 M solution in hexane, 2.5 equiv) in THF (20 mL) in a three-neck round bottom flask was added dropwise acetonitrile (30 mmol, 3.0 equiv) at -78 °C, and the reaction mixture was stirred for 1 h. Then a solution of ethyl benzoate (10 mmol, 1.0 equiv) in THF (10 mL) was added slowly, and the reaction mixture was stirred for another 2 h at -78 °C. The reaction was quenched with H₂O (20 mL) and the solvent was removed in vacuo. The resulting mixture was diluted with EtOAc (20 mL) and the organic layer was separated. The water layer was extracted with EtOAc (3×20 mL), and the combined organic phase was washed with brine, dried over MgSO₄, and concentrated in vacuo. The residue was purified by column chromatography on silica gel (petroleum ether : ethyl acetate = 3:1) to obtain the corresponding 3-oxo-3-propanenitrile.



3-Oxo-3-(*o*-tolyl)propanenitrile (2b):^[1] General procedure **A** was followed on a 10.0 mmol scale. The product 2b was obtained as a yellow solid (1.1 g, 70%). Mp: 81~82 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.64 (d, *J* = 7.6 Hz, 1H), 7.50 (t, *J* = 7.6 Hz, 1H), 7.34 (t, *J* = 7.6 Hz, 2H), 4.08 (s, 2H), 2.58 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 189.4, 140.4, 133.8, 133.3, 132.8, 129.3, 126.2, 114.2, 31.5, 21.8. HRMS (ESI) calcd for C₁₀H₁₀NO [M+H]⁺ 160.0762, found 160.0766.



3-Oxo-3-(*m***-tolyl)propanenitrile (2c):**^[1] General procedure **A** was followed on a 10.0 mmol scale. The product **2c** was obtained as a yellow solid (0.6 g, 37%). Mp: 68~69 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.77–7.68 (m, 2H), 7.48 (d, *J* = 7.6 Hz, 1H), 7.42 (t, *J* = 7.6 Hz, 1H), 4.10 (s, 2H), 2.44 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 187.4, 139.2, 135.5, 134.3, 129.0, 128.9, 125.7, 114.0, 29.4, 21.3. HRMS (ESI) calcd for C₁₀H₁₀NO [M+H]⁺ 160.0762, found 160.0763.



3-Oxo-3-(*p*-tolyl)propanenitrile (2d):^[1] General procedure **A** was followed on a 10.0 mmol scale. The product 2d was obtained as a yellow solid (1.8 g, 84%). Mp: 99~100 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.83 (d, *J* = 8.0 Hz, 2H), 7.33 (d, *J* = 8.4 Hz, 2H), 4.08 (s, 2H), 2.49 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 186.74 145.99 131.86 129.83 128.60 114.02 29.29 21.80. HRMS (ESI) calcd for C₁₀H₁₀NO [M+H]⁺ 160.0762, found 160.0765.



3-Oxo-3-(*p*-tolyl)**propanenitrile (2e):**^[2] General procedure **A** was followed on a 10.0 mmol scale. The product **2e** was obtained as a yellow solid (0.7 g, 35%). Mp: 87~88 °C. ¹H NMR (500 MHz, CDCl₃) *δ* 7.51–7.40 (m, 3H), 7.24–7.18 (m, 1H), 4.10 (s, 2H), 3.88 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 187.0, 160.1, 135.5, 130.1, 121.2, 120.9, 113.8, 112.6, 55.5, 29.5. HRMS (ESI) calcd for C₁₀H₉NNaO₂ [M+Na]⁺ 198.0531, found 198.0536.



3-(4-(Tert-butyl)phenyl)-3-oxopropanenitrile (2g):^[3] General procedure **B** was followed on a 10.0 mmol scale. The product **2g** was obtained as a yellow solid (0.9 g, 40%). Mp: 73~74 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.94–7.82 (m, 2H), 7.62–7.48 (m, 2H), 4.09 (s, 2H), 1.37 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 186.7, 158.8, 131.7, 128.5, 126.1, 114.0, 35.3, 30.9, 29.3. HRMS (ESI) calcd for C₁₃H₁₅NNaO [M+Na]⁺ 224.1051, found 224.1051.



3-Oxo-3-(4-(trifluoromethoxy)phenyl)propanenitrile (2h):^[4] General procedure **B** was followed on a 10.0 mmol scale. The product **2h** was obtained as a yellow solid (1.61 g, 64%). Mp: 72~73 °C. ¹H NMR (500 MHz, CDCl₃) δ 8.08–7.95 (m, 2H), 7.37 (d, *J* = 8.0 Hz, 2H), 4.11 (s, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 185.7, 153.7, 132.3, 130.6, 123.2, 120.2 (q, *J* = 8.1 Hz), 113.4, 29.4. ¹⁹F NMR (471 MHz, CDCl₃): δ –57.6. HRMS (ESI) calcd for C₁₀H₆F₃NNaO₂ [M+Na]⁺ 252.0248, found 252.0253.



3-(2-Fluorophenyl)-3-oxopropanenitrile (2i):^[1] General procedure **B** was followed on a 20.0 mmol scale. The product **2i** was obtained as a yellow solid (1.1 g, 69.9%). Mp: 60–61 °C , ¹H NMR (500 MHz, CDCl₃) δ 7.97 (td, J = 7.6, 2.0 Hz, 1H), 7.68–7.63 (m, 1H), 7.38–7.29 (m, 1H), 7.26–7.17 (m, 1H), 4.12 (d, J = 2.8 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 185.1 (d, J = 3.8 Hz), 162.2 (d, J = 3.8 Hz), 253.3 (d, J = 9.5 Hz), 131.13 (d, J = 1.6 Hz), 125.18 (d, J = 3.3 Hz), 122.75 (d, J = 12.3 Hz), 116.9 (d, J = 23.4 Hz), 113.53 (d, J = 3.8 Hz), 33.66 (d, J = 11.6 Hz). ¹⁹F NMR (471 MHz, CDCl₃): δ –109.1. HRMS (ESI) calcd for C₉H₇FNO [M+H]⁺ 164.0512, found 164.0510.



3-(3-Fluorophenyl)-3-oxopropanenitrile (2j):^[5] General procedure **A** was followed on a 10.0 mmol scale. The product **2j** was obtained as a yellow solid (1.1 g, 84.0%). Mp: 71~72 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.72 (d, *J* = 7.8 Hz, 1H), 7.66–7.61 (m, 1H), 7.54 (td, *J* = 8.0, 5.5 Hz, 1H), 7.39 (td, *J* = 8.2, 2.5 Hz, 1H), 4.12 (s, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 186.1 (d, *J* = 2.4 Hz), 162.9 (d, *J* = 248.3 Hz), 136.1 (d, *J* = 6.6 Hz), 130.9 (d, *J* = 7.7 Hz), 124.2 (d, *J* = 3.1 Hz), 121.9 (d, *J* = 21.2 Hz), 115.2 (d, *J* = 22.6 Hz), 113.50 (s), 29.65 (s). ¹⁹F NMR (471 MHz, CDCl₃): δ –110.4. HRMS (ESI) calcd for C₉H₇FNO [M+H]⁺ 164.0512, found 164.0515.



3-(3-Chlorophenyl)-3-oxopropanenitrile (21):^[1] General procedure **A** was followed on a 10.0 mmol scale. The product **2m** was obtained as a yellow solid (1.1 g, 60%). ¹H NMR (500 MHz, CDCl₃) δ 7.91 (t, J = 1.6 Hz, 1H), 7.81 (d, J = 7.8 Hz, 1H), 7.69–7.63 (m, 1H), 7.50 (t, J = 7.9 Hz, 1H), 4.11 (s, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 186.1, 135.7, 135.6, 134.7, 130.5, 128.5, 126.5, 113.4, 29.6. HRMS (ESI) calcd for C₉H₆F₂NO [M+H]⁺ 182.0417, found 182.0423.



3-Oxo-3-(4-(trifluoromethyl)phenyl)propanenitrile (20):^[6] General procedure **A** was followed on a 10.0 mmol scale. The product **20** was obtained as a yellow solid (1.0 g, 48%). Mp: 143~144 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.07 (d, *J* = 8.4 Hz, 2H), 7.83 (d, *J* = 8.4 Hz, 2H), 4.15 (d, *J* = 1.6 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 186.3, 136.8, 135.9 (q, *J* = 52.6 Hz), 128.8, 126.2 (q, *J* = 29.0 Hz), 123.5 (q, *J* = 271.4 Hz), 122.1, 119.9, 113.1, 29.6. ¹⁹F NMR (471 MHz, CDCl₃): δ – 63.4. HRMS (ESI) calcd for C₁₀H₇F₃NO [M+H]⁺ 213.0474, found 213.0470.



3-(2,4-Dichlorophenyl)-3-oxopropanenitrile (2p):^[7] General procedure **A** was followed on a 10.0 mmol scale. The product **2p** was obtained as a yellow solid (1.1 g, 50%). Mp: 52~53 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.65 (d, J = 8.4 Hz, 1H), 7.54–7.51 (m, 1H), 7.43–7.39 (m, 1H), 4.16 (d, J = 0.8 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 188.1, 139.9, 133.7, 132.9, 131.7, 130.9, 128.0, 113.1, 33.0. HRMS (ESI) calcd for C₉H₆Cl₂NO [M+H]⁺ 213.9826, found 213.9827.



3-(3,4-Difluorophenyl)-3-oxopropanenitrile (2q):^[8] General procedure **B** was followed on a 10.0 mmol scale. The product **2q** was obtained as a yellow solid (0.9 g, 50%). Mp: 65~66 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.86–7.77 (m, 1H), 7.75–7.71 (m, 1H), 7.38–7.32 (m, 1H), 4.11 (s, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 184.9, 144.5 (dd, *J* = 258.8, 12.8 Hz), 150.6 (dd, *J* = 251.4, 13.1 Hz), 131.3 (t, *J* = 4.5 Hz), 125.75 (q, *J* = 7.7 Hz), 118.2 (d, *J* = 18.1 Hz), 117.9 (dd, *J* = 18.3, 2.1 Hz), 113.3, 29.4. ¹⁹F NMR (376 MHz, CDCl₃): δ –126.1 (d, *J* = 21.0 Hz), –134.3 (d, *J* = 26.7 Hz). HRMS (ESI) calcd for C₉H₆F₂NO [M+H]⁺ 182.0417, found 182.0423.



3-(Naphthalen-1-yl)-3-oxopropanenitrile (2r):^[9] General procedure **A** was followed on a 10.0 mmol scale. The product **2r** was obtained as a yellow solid (1.1 g, 58%). Mp: 92~93 °C. ¹H NMR (500 MHz, CDCl₃) δ 8.83 (d, J = 8.4 Hz, 1H), 8.11 (d, J = 8.4 Hz, 1H), 7.96–7.85 (m, 2H), 7.71–7.65 (m, 1H), 7.63–7.59 (m, 1H), 7.55 (t, J = 8.0 Hz, 1H), 4.22 (s, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 189.6, 135.2, 134.0, 131.4, 130.3, 129.6, 128.7, 127.1, 125.6, 124.2, 114.2, 31.8. HRMS (ESI) calcd for C₁₃H₁₀NO [M+H]⁺ 196.0762, found 196.0763.



3-(Naphthalen-2-yl)-3-oxopropanenitrile (2s):^[1] General procedure **B** was followed on a 10.0 mmol scale. The product **2s** was obtained as a yellow solid (1.2 g, 61%). Mp:119~120 °C. ¹H NMR (500 MHz, CDCl₃) δ 8.41 (s, 1H), 8.00–7.90 (m, 4H), 7.77–7.52 (m, 2H), 4.23 (s, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 187.1, 136.1, 132.2, 131.6, 130.7, 129.7, 129.5, 127.9, 127.4, 123.3, 114.0, 29.4. HRMS (ESI) calcd for C₁₃H₁₀NO [M+H]⁺ 196.0762, found 196.0767.



3-(Furan-3-yl)-3-oxopropanenitrile (2v):^[1] General procedure B was followed on a 10.0 mmol

scale. The product **2v** was obtained as a yellow solid (0.6 g, 39%). Mp: 71~72 °C. ¹H NMR (500 MHz, CDCl₃) δ 8.19 (s, 1H), 7.61–7.41 (m, 1H), 6.81 (d, *J* = 2.5 Hz, 1H), 4.00–3.73 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 181.3, 148.3, 148.2, 145.0, 125.6, 113.6, 108.5, 30.3. HRMS (ESI) calcd for C₇H₅NNaO₂ [M+Na]⁺ 158.0218, found 158.0220.



3-Oxo-3-(thiophen-3-yl)propanenitrile (2w):^[1] General procedure **B** was followed on a 10.0 mmol scale. The product **2w** was obtained as a yellow solid (0.8 g, 53%). Mp: 82~83 °C. ¹H NMR (500 MHz, CDCl₃) δ 8.28–8.08 (m, 1H), 7.67–7.52 (m, 1H), 7.42 (q, *J* = 5.1, 2.8 Hz, 1H), 4.03 (s, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 181.1, 139.2, 134.1, 127.6, 126.8, 113.9, 30.2. HRMS (ESI) calcd for C₇H₆NOS [M+Na]⁺ 152.0170, found 152.0168.



3-Oxo-5-phenylpentanenitrile (2z):^[10] General procedure **A** was followed on a 10.0 mmol scale. The product **2z** was obtained as a yellow solid (0.8 g, 47%). Mp: 231~232 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.32 (t, *J* = 7.5 Hz, 2H), 7.25 (d, *J* = 7.0 Hz, 1H), 7.22 (t, *J* = 7.0 Hz, 2H), 3.43 (s, 2H), 3.01–2.89 (m, 4H). ¹³C NMR (125 MHz, CDCl₃) δ 197.0, 196.9, 139.7, 128.7, 128.3, 126.6, 113.8, 113.7, 43.6, 32.2, 29.4. HRMS (ESI) calcd for C₁₁H₁₂NO [M+Na]⁺174.0919, found 174.0920.

3. General Procedure for the Preparation of Allyl Biscarbonates



A representative procedure for the hydrolysis of these acetylated compounds to **1** was as follows: To a solution of a mixture of allylic bisacetates^[11] (10 mmol) in methanol (50 mL), 2N NaOH aq. (12 mL) was added. The mixture was stirred at reflux for 30 min. After cooling to r.t., the MeOH was removed under reduced pressure and extracted with ethyl acetate six times. The combined organic layer was dried over Na₂SO₄, filtered and concentrated to give the crude product, which was used in the next step without further purification. The mixture of the crude allylic bisalcohols and DBU (10 mmol) in dimethyl carbonate (20 mL) was stirred under reflux for 12 h. The mixture was evaporated in vacuo to remove dimethyl carbonate. The residue was purified by flash silica gel column chromatography (PE/EA = 10/1) to give **1**.



cis-1,4-Dimethylcarbonate-2-cyclohexene (1a): General procedure was followed on a 10.0 mmol scale. The product 1a was obtained as a colorless oil (1.0 g, 43%). ¹H NMR (400 MHz, CDCl₃) δ 5.99 (s, 2H), 5.10 (d, *J* = 1.2 Hz, 2H), 3.79 (s, 6H), 2.03–1.89 (m, 4H). ¹³C NMR (100 MHz, CDCl₃) δ 155.3, 130.0, 70.9, 54.7, 24.6. IR (KBr) (v/cm⁻¹): 2959, 1343, 1314, 1053, 939, 916, 758. HRMS (ESI) calcd for C₁₀H₁₄NaO₆ [M+Na]⁺ 253.0683, found 253.0691.



cis-1,4-Dimethylcarbonate-2-cyclopentene (1b): General procedure was followed on a 10.0 mmol scale. The product 1b was obtained as a colorless oil (0.4 g, 19%). ¹H NMR (400 MHz, CDCl₃) δ 6.14 (d, J = 0.8 Hz, 2H), 5.51–5.39 (m, 2H), 3.89–3.68 (m, 6H), 3.00–2.82 (m, 1H), 1.99–1.82 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 155.2, 134.5, 79.7, 54.7, 36.8. IR (KBr) (v/cm⁻¹): 2959, 1746, 1338, 1255, 792. HRMS (ESI) calcd for C₉H₁₂NaO₆ [M+Na]⁺ 239.0526, found 239.0531.



cis-1,4-Dimethylcarbonate-2-cycloheptene (1c): General procedure was followed on a 10.0 mmol scale. The product 1c was obtained as a white solid (0.6 g, 25%). Mp: 89~90 °C. ¹H NMR (400 MHz, CDCl₃) δ 5.76 (s, 2H), 5.26–5.21 (m, 2H), 3.80 (s, 6H), 2.09–2.03 (m, 1H), 2.01–1.95 (m, 2H), 1.86–1.76 (m, 1H), 1.69–1.64 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 155.1, 132.0, 77.5,

54.8, 32.2, 22.8. IR (KBr) (v/cm⁻¹): 2956, 1747, 1631, 1443, 1328, 973. HRMS (ESI) calcd for $C_{11}H_{16}NaO_6[M+Na]^+$ 267.0839, found 267.0943.

4. General Procedure for the Pd-Catalyzed Asymmetric Allylic Substitution

4.1 Optimization of the reaction conditions

At the outset, *cis*-cyclohex-2-ene-1,4-diyl dicarbonate (1a) and benzoylacetonitrile (2a) were chosen as the model substrates to investigate the reaction conditions. In the presence of 2.5 mol% [Pd(C₃H₅)Cl]₂, 3.0 mol% of L1, and 2.0 equiv of DBU,^{11h} the reaction of 1a and 2a in dioxane for 24 h gave chiral bicyclic dihydrofuran 3a in 71% yield and 93% ee (Table 1, entry 1). Encouraged by these results, further optimization of the reaction conditions was carried out. When the leaving group of 2a was re-placed by an Ac substituent, the reaction proceeded but with a decline in both yield and enantioselectivity (entry 2). Next, the effect of different solvents on the reaction was investigated, and dioxane was found to be the solvent of choice (entry 1 and entries 3-7). Surprisingly, when the loading of DBU was lowered to 1.0 equiv, the yield of **3a** further increased (85% isolated yield, entry 8) and was accompanied by a slight increase in ee (94% ee). Notably, the reaction also occurred with a slightly increased yield and ee in the absence of base (entry 9). Careful investigations of a variety of metallocene-based planar chiral ligands (L1~4) were finally carried out. It was shown that 'Bu-RuPHOX (L1) was the most efficient ligand for this reaction, which afforded 3a in 87% yield and with 95% ee (entries 9-12). According to observations in the optimization studies, the best reaction conditions were identified as the following: reaction of 1a and 2a in dioxane with 2.5 mol% of $[Pd(\eta^3-C_3H_5)Cl]_2$, 3.0 mol% of **RuPHOX** at rt for 24 h. Table S1. Optimization of the Reaction Conditions.^a



4	L1	DBU	DCE	63	89
5	L1	DBU	CH_2Cl_2	54	92
6	L1	DBU	toluene	trace	
7	L1	DBU	MeCN	trace	
8 ^e	L1	DBU	dioxane	85	94
9ſ	L1		dioxane	87	95
10	L2		dioxane	72	78
11	L3		dioxane	83	92
12	L4		dioxane	87	79

^{*a*}Reaction conditions: **1a** (0.24 mmol), **2a** (0.2 mmol), $[Pd(\eta^3-C_3H_5)Cl]_2$ (2.5 mol%), ligand (3.0 or 6.0 mol%), DBU (2.0 equiv) in dioxane (2 mL) at rt for 24 h. ^{*b*}Isolated yield; All of the reactions afforded >20:1 dr. ^{*c*}Determined by chiral HPLC analysis using OD-H chiral column. The absolute configuration of **3a** was determined according to X-ray analysis of **3f** and is shown in Supporting Information.¹⁴ ^{*d*}Ac instead of CO₂Me ^{*e*}DBU (1.0 equiv). ^{*f*}Without a base.

Scheme S1. Proposed Reaction Mechanism^[12]



Scheme S1. Proposed Reaction Mechanism

A plausible catalytic cycle for the formation of chiral bicyclic dihydrofuran **3a** is depicted in Scheme S1. Obviously, **3a** is constructed via an allylic alkylation followed by an intramolecular *O*allylic alkylation. First, combination of *cis*-**1a** with L_2Pd^0 provide allyl-Pd complex **A**. The process represents an asymmetric desymmetrization of *cis*-**1a** because L_2Pd^0 prefers to attack the *R*-chiral carbon of **1a** in the presence of a chiral catalyst. Complex **A** then reacts with nucleophile **2a** to give alkylated intermediate **B**. Finally, **B** takes part in the next intramolecular *O*-allylic alkylation, giving the chiral bicyclic dihydrofuran **3a** in high yield as well as excellent dr via allyl-Pd complex **C**.

4.2 General procedure for the Pd-catalyzed asymmetric allylic substitution



General procedure: A flame-dried Schlenk tube equipped with a magnetic stirring bar, was charged with a mixture of $[Pd(\eta^3-C_3H_5)Cl]_2$ (1.83 mg, 2.5 mol%) and L1 (5.1 mg, 3.0 mol%). After being evacuated and backfilled with nitrogen three times, 1,4-dioxane (2 mL) was added to the Schlenk tube and the mixture was stirred at room temperature under a N₂ atmosphere for 1 h. Allylic biscarbonate 1 (0.24 mmol, 1.2 equiv) was added via a syringe followed by addition of benzoyl acetonitrile 2 (0.2 mmol) under a N₂ atmosphere. The reaction mixture was allowed to stir under a N₂ atmosphere at room temperature for 24 h. 1,4-dioxane was evaporated in vacuo and the residue was purified by flash silica gel column chromatography (PE/EA = 20/1) to give product **3**.



(*3aS*, *7aS*)-2-Phenyl-3a, 4, 5, 7a-tetrahydrobenzofuran-3-carbonitrile (3a): Colorless oil (39.0 mg, 87%). ¹H NMR (400 MHz, CDCl₃) δ 8.02–7.90 (m, 2H), 7.56–7.40 (m, 3H), 6.30–6.13 (m, 1H), 5.94 (ddt, *J* = 10.1, 3.6, 1.9 Hz, 1H), 5.15–5.06 (m, 1H), 3.40 (td, *J* = 8.9, 4.6 Hz, 1H), 2.33–2.19 (m, 1H), 2.01 (dddt, *J* = 8.1, 6.8, 5.5, 3.4 Hz, 2H), 1.80–1.65 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 166.9, 134.6, 131.3, 128.6, 128.4, 127.1, 122.9, 117.7, 84.7, 78.7, 42.0, 29.7, 23.9, 22.0. IR (KBr) (v/cm⁻¹): 2932, 2199, 1578, 1221, 1048, 917, 700. HRMS (ESI) calcd for C₁₅H₁₄NO [M+H]⁺ 224.1075, found 224.1077.HPLC (Daicel Chiralcel OD-H, *n*-hexane/*i*-PrOH = 99/1, UV = 254 nm, flow rate = 0.8 mL/min) t_{R1} = 8.766 min (minor) and t_{R2} = 9.493 min (major), ee = 95%. [α] $\frac{25}{20}$ = -98.7 (*c* 0.4, CHCl₃).



(*3aS*, *7aS*)-2-(*o*-Tolyl)-3a,4,5,7a-tetrahydrobenzofuran-3-carbonitrile (3b): Colorless oil (42.4 mg, 89%). ¹H NMR (500 MHz, CDCl₃) δ 7.56–7.49 (m, 1H), 7.36 (t, *J* = 8.0 Hz, 1H), 7.29–7.24

(m, 2H), 6.28–6.21 (m, 1H), 5.93–5.90 (m, 1H), 5.21–5.11 (m, 1H), 3.42 (td, J = 8.5, 4.5 Hz, 1H), 2.42 (s, 3H), 2.32–2.21 (m, 1H), 2.10–1.94 (m, 2H), 1.81–1.69 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 170.6, 137.2, 134.5, 130.9, 130.7, 129.2, 128.1, 125.8, 123.0, 116.8, 88.5, 79.6, 41.3, 24.0, 21.9, 20.1. IR (KBr) (v/cm⁻¹): 2922, 2360, 2204, 1631, 1582, 1345, 792, 723. HRMS (ESI) calcd for C₁₆H₁₆NO [M+H]⁺ 238.1232, found 238.1234. HPLC (Daicel Chiralcel OJ-H, *n*-hexane/*i*-PrOH = 99/1, UV = 254 nm, flow rate = 1.0 mL/min) t_{R1} = 16.481 min (minor) and t_{R2} = 22.916 min (major), ee = 93%. [α]²⁵ = -101.8 (*c* 0.20, CHCl₃).



(*3aS*, *7aS*)-2-(*m*-Tolyl)-3a,4,5,7a-tetrahydrobenzofuran-3-carbonitrile (3c): Colorless oil (43.5 mg, 91%). ¹H NMR (500 MHz, CDCl₃) δ 7.88–7.68 (m, 2H), 7.41–7.22 (m, 2H), 6.33–6.17 (m, 1H), 5.95–5.92 (m, 1H), 5.15–5.01 (m, 1H), 3.39 (td, *J* = 8.5, 5.0 Hz, 1H), 2.41 (s, 3H), 2.30–2.16 (m, 1H), 2.06–1.96 (m, 2H), 1.72–1.65 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 167.0, 138.4, 134.5, 132.1, 128.5, 128.3, 127.5, 124.3, 122.9, 117.7, 84.5, 78.6, 41.9, 23.9, 22.0, 21.4. IR (KBr) (v/cm⁻¹): 2922, 2793, 2359, 2199, 1194, 918, 794, 699. HRMS (ESI) calcd for C₁₆H₁₆NO [M+H]⁺238.1232, found 238.1234. HPLC (Daicel Chiralcel OJ-H, *n*-hexane/*i*-PrOH = 99/1, UV = 254 nm, flow rate = 1.0 mL/min) t_{R1} = 10.964 min (minor) and t_{R2} = 13.685 min (major), ee = 97%. [α]²⁵_D = -150.7 (*c* 0.22, CHCl₃).



(*3aS*, *7aS*)-2-(*p*-Tolyl)-3a,4,5,7a-tetrahydrobenzofuran-3-carbonitrile (3d): Colorless oil (44.8 mg, 94%). ¹H NMR (400 MHz, CDCl₃) δ 7.95–7.92 (m, 2H), 6.97–6.93 (m, 2H), 6.27–6.16 (m, 1H), 5.93 (ddt, *J* = 10.1, 3.6, 1.9 Hz, 1H), 5.07–5.05 (m, 1H), 3.87 (s, 3H), 3.37 (td, *J* = 8.9, 4.6 Hz, 1H), 2.29–2.20 (m, 1H), 2.06–1.93 (m, 2H), 1.72–1.61 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 167.0, 141.8, 134.5, 129.3, 127.1, 125.6, 122.9, 117.9, 83.8, 78.6, 41.9, 31.4, 29.7, 23.9, 22.0, 21.6. IR (KBr) (v/cm⁻¹): 2920, 2846, 2341, 1495, 1020, 767, 690, 609. HRMS (ESI) calcd for C₁₆H₁₆NO [M+H]⁺ 238.1232, found 238.1235. HPLC (Daicel Chiralcel OJ-H, *n*-hexane/*i*-PrOH = 99/1, UV = 254 nm, flow rate = 1.0 mL/min) t_{R1} = 10.964 min (minor) and t_{R2} = 13.685 min (major), ee = 96%.

[
$$\alpha$$
] $\overset{25}{D} = -79.2 (c \ 0.30, \text{CHCl}_3).$



(*3aS*, *7aS*)-2-(3-Methoxyphenyl)-3a,4,5,7a-tetrahydrobenzofuran-3-carbonitrile (3e): Colorless oil (46.4 mg, 92%). ¹H NMR (500 MHz, CDCl₃) δ 7.58 (d, J = 8.0 Hz, 1H), 7.51–7.44 (m, 1H), 7.36 (t, J = 8.0 Hz, 1H), 7.05–6.99 (m, 1H), 6.24–6.20 (m, 1H), 5.93 (ddd, J = 10.0, 3.5, 2.0 Hz, 1H), 5.09 (dd, J = 9.0, 2.0 Hz, 1H), 3.86 (s, 3H), 3.39 (td, J = 9.0, 4.5 Hz, 1H), 2.30–2.18 (m, 1H), 2.09–1.93 (m, 2H), 1.72–1.65 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 166.7, 159.6, 134.5, 129.6, 129.5, 122.9, 119.5, 117.8, 117.6, 111.6, 84.9, 78.7, 55.4, 41.9, 23.8, 22.0. IR (KBr) (v/cm⁻¹): 3854, 3036, 1593, 1462, 1187, 987, 875, 730. HRMS (ESI) calcd for C₁₆H₁₆NO [M+H]⁺254.1181, found 254.1187. HPLC (Daicel Chiralcel OJ-H, *n*-hexane/*i*-PrOH = 94/6, UV = 254 nm, flow rate

= 1.0 mL/min) $t_{R1} = 14.148 \text{ min (minor)}$ and $t_{R2} = 15.523 \text{ min (major)}$, ee = 96%. [α] $^{25}_{D} = -132.8$ (*c* 0.26, CHCl₃).



(*3aS*, *7aS*)-2-(4-Methoxyphenyl)-3a,4,5,7a-tetrahydrobenzofuran-3-carbonitrile (3f): White solid (44.0 mg, 88%). Mp: 85–86 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.95–7.92 (m, 2H), 7.02–6.93 (m, 2H), 6.24–6.20 (m, 1H), 5.93 (ddt, *J* = 10.1, 3.6, 1.9 Hz, 1H), 5.07–5.05 (m, 1H), 3.87 (s, 3H), 3.37 (td, *J* = 8.8, 4.4 Hz, 1H), 2.29–2.20 (m, 1H), 2.05–1.99 (m, 2H), 1.72–1.64 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 166.8, 161.9, 134.5, 128.9, 123.0, 121.0, 118.2, 113.9, 82.5, 78.5, 55.4, 41.8, 24.0, 22.1. IR (KBr) (v/cm⁻¹): 3800, 2966, 1593, 1460, 1185, 976, 855, 732. HRMS (ESI) calcd for C₁₆H₁₆NO [M+H]⁺ 254.1181, found 254.1182. HPLC (Daicel Chiralcel OJ-H, *n*-hexane/*i*-PrOH = 99/1, UV = 254 nm, flow rate = 1.0 mL/min) t_{R1} = 17.617 min (minor) and t_{R2} = 26.526 min (major),

ee = 96%. [α] $\frac{25}{D}$ = -150.6 (*c* 1.00, CHCl₃).



(3aS, 7aS)-2-(4-(Tert-butyl)phenyl)-3a,4,5,7a-tetrahydrobenzofuran-3-carbonitrile (3g): Colorless oil (50.4 mg, 90%). ¹H NMR (500 MHz, CDCl₃) δ 7.91 (d, J = 8.5 Hz, 2H), 7.47 (d, J = 8.5 Hz, 2H), 6.23–6.20 (m, 1H), 5.94–5.91 (m, 1H), 5.08 (d, J = 8.5 Hz, 1H), 3.39 (td, J = 8.5, 4.5 Hz, 1H), 2.32–2.16 (m, 1H), 2.10–1.93 (m, 2H), 1.77–1.64 (m, 1H), 1.35 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ 167.0, 154.9, 134.4, 126.9, 125.6, 125.5, 123.0, 117.8, 83.9, 78.6, 41.8, 35.0, 31.1, 23.9, 21.9. IR (KBr) (v/cm⁻¹): 2960, 21198, 1922, 1457, 1363, 1119, 918, 776. HRMS (ESI) calcd for C₁₉H₂₂NO [M+H]⁺280.1701, found 280.1704. HPLC (Daicel Chiralcel OJ-H, *n*-hexane/*i*-PrOH = 99/1, UV = 254 nm, flow rate = 1.0 mL/min) t_{R1} = 9.500 min (minor) and t_{R2} = 10.274 min (major),

ee = 96%. [α] $D^{25} = -129.2$ (*c* 0.36, CHCl₃).



(3aS, 7aS)-2-(4-(Trifluoro(oxo)-l6-methyl)phenyl)-3a,4,5,7a-tetrahydrobenzofuran-3-

carbonitrile (3h): Colorless oil (56.0 mg, 91%). ¹H NMR (400 MHz, CDCl₃) δ 8.12–7.93 (m, 2H), 7.40–7.20 (m, 2H), 6.31–6.11 (m, 1H), 5.92 (ddt, *J* = 10.0, 3.6, 2.0 Hz, 1H), 5.22–5.01 (m, 1H), 3.42 (td, *J* = 9.2, 4.8 Hz, 1H), 2.37–2.19 (m, 1H), 2.15–1.93 (m, 2H), 1.74–1.66 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 165.3, 151.0 (d, *J* = 7.2 Hz), 134.7, 128.9, 126.8, 122.7, 12.7, 120.3 (q, *J* = 205.5 Hz), 117.2, 85.4, 78.9, 41.9, 23.8, 21.9. ¹⁹F NMR (376 MHz, CDCl₃): δ –57.6. IR (KBr) (v/cm⁻¹): 2931, 2360, 2201, 1618, 1508, 1212, 1169, 917, 856, 662. HRMS (ESI) calcd for C₁₆H₁₃F₃NO₂ [M+H]⁺ 308.0898, found 308.0898. HPLC (Daicel Chiralcel OJ-H, *n*-hexane/*i*-PrOH = 99/1, UV = 254 nm, flow rate = 1.0 mL/min) t_{R1} = 8.213 min (minor) and t_{R2} = 8.679 min (major),

ee = 97%. [α] $D^{25} = -109.5$ (*c* 0.12, CHCl₃).



(*3aS*, *7aS*)-2-(2-Fluorophenyl)-3a,4,5,7a-tetrahydrobenzofuran-3-carbonitrile (3i): White solid (43.0 mg, 85%). Mp: 88–89 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.67 (td, *J* = 7.6, 2.0 Hz, 1H), 7.48 – 7.45 (m, 1H), 7.24–7.15 (m, 2H), 6.27–6.23 (m, 1H), 5.95–5.91 (m, 1H), 5.20–5.07 (m, 1H), 3.43 (td, *J* = 8.8, 4.4 Hz, 1H), 2.32–2.23 (m, 1H), 2.09–1.96 (m, 2H), 1.77–1.68 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 163.3 (d, *J* = 2.6 Hz), 161.1, 158.6, 134.7, 132.8 (d, *J* = 8.6 Hz), 129.7 (d, *J* = 2.2 Hz), 124.2 (d, *J* = 3.7 Hz), 122.7, 116.7 (dd, *J* = 39.1, 21.5 Hz), 116.1 (d, *J* = 1.3 Hz), 89.4 (d, *J* = 2.2 Hz), 79.2, 41.9, 23.8, 21.9. ¹⁹F NMR (376 MHz, CDCl₃): δ –107.4. IR (KBr) (v/cm⁻¹): 2920,

2207, 1489, 1268, 914, 738. HRMS (ESI) calcd for $C_{15}H_{13}FNO [M+H]^+242.0981$, found 242.0980. HPLC (Daicel Chiralcel OD-H, *n*-hexane/*i*-PrOH = 99/1, UV = 254 nm, flow rate = 1.0 mL/min)

 $t_{R1} = 10.601 \text{ min (minor)}$ and $t_{R2} = 11.731 \text{ min (major)}$, ee = 94%. [α] $D^{25} = -163.4$ (*c* 0.11, CHCl₃).



(*3aS*, *7aS*)-2-(3-Fluorophenyl)-3a,4,5,7a-tetrahydrobenzofuran-3-carbonitrile (3j): Colorless oil (40.0 mg, 89%). ¹H NMR (400 MHz, CDCl₃) δ 7.82 (d, J = 8.0 Hz, 1H), 7.63–7.60 (m, 1H), 7.43 (td, J = 8.0, 6.0 Hz, 1H), 7.18 (td, J = 8.4, 2.4 Hz, 1H), 6.26–6.22 (m, 1H), 5.95–5.91 (m, 1H), 5.13–5.10 (m, 1H), 3.42 (td, J = 9.2, 4.8 Hz, 1H), 2.30–2.22 (m, 1H), 2.07–1.97 (m, 2H), 1.74–1.65 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 165.4 (d, J = 1.9 Hz), 163.5, 161.5, 134.7, 130.3 (d, J = 8.1 Hz), 122.9 (d, J = 2.3 Hz), 122.7, 118.2 (d, J = 16.8 Hz), 117.1, 114.0 (d, J = 19.0 Hz), 85.9, 78.8, 42.0, 23.8, 21.9. ¹⁹F NMR (376 MHz, CDCl₃): δ –111.6. IR (KBr) (v/cm⁻¹): 2848, 2341, 1949, 1447, 1020, 936, 603. HRMS (ESI) calcd for C₁₅H₁₃FNO [M+H]⁺242.0981, found 242.0986. HPLC (Daicel Chiralcel IC-3, *n*-hexane/*i*-PrOH = 99/1, UV = 254 nm, flow rate = 0.8 mL/min) t_{R1} = 21.611

min (minor) and $t_{R2} = 22.905$ min (major), ee = 94%. [α] $^{25}_{D} = -163.4$ (c 0.29, CHCl₃).



(*3aS*, *7aS*)-2-(4-Fluorophenyl)-3a,4,5,7a-tetrahydrobenzofuran-3-carbonitrile (3k): Colorless oil (46.3 mg, 95%). ¹H NMR (400 MHz, CDCl₃) δ 8.00–7.96 (m, 2H), 7.16–7.10 (m, *J* = 2H), 6.24–6.21 (m, 1H), 5.94–5.90 (m, 1H), 5.10–5.08 (m, 1H), 3.40 (td, *J* = 8.9, 4.6 Hz, 1H), 2.30–2.21 (m, 1H), 2.07–1.95 (m, 2H), 1.73–1.64 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 165.8, 165.2, 163.2, 134.6, 129.4 (d, *J* = 8.8 Hz), 124.6 (d, *J* = 3.3 Hz), 122.8, 117.59, 115.88, 115.7, 84.4 (d, *J* = 1.5 Hz), 78.80, 41.9, 23.8, 21.9. ¹⁹F NMR (376 MHz, CDCl₃): δ –107.0. IR (KBr) (v/cm⁻¹): 2929, 2200, 1594, 1361, 957, 743. HRMS (ESI) calcd for C₁₅H₁₃FNO [M+H]⁺242.0981, found 242.0984. HPLC (Daicel Chiralcel IC-3, *n*-hexane/*i*-PrOH = 99/1, UV = 254 nm, flow rate = 0.8 mL/min) t_{R1} = 18.201

min (minor) and $t_{R2} = 19.316$ min (major), ee = 96%. [α] $^{25}_{D} = -164.7$ (c 0.28, CHCl₃).



(*3aS*, *7aS*)-2-(3-Chlorophenyl)-3a,4,5,7a-tetrahydrobenzofuran-3-carbonitrile (3l): Colorless oil (42.0 mg, 82%). ¹H NMR (500 MHz, CDCl₃) δ 7.92 (dd, J = 8.0, 1.0 Hz, 1H), 7.88 (d, J = 2.0 Hz, 1H), 7.45 (dd, J = 8.0, 1.0 Hz, 1H), 7.41–7.37 (m, 1H), 6.25–6.22 (m, 1H), 5.94–5.91 (m, 1H), 5.11 (d, J = 9.0 Hz, 1H), 3.41 (td, J = 9.0, 4.0 Hz, 1H), 2.26–2.22 (m, 1H), 2.10–1.93 (m, 2H), 1.72–1.65 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 165.2, 134.8, 134.7, 131.2, 130.0, 129.9, 127.0, 125.2, 122.7, 117.0, 85.9, 78.8, 42.0, 23.8, 21.9. IR (KBr) (v/cm⁻¹): 3448, 2930, 2201, 1616, 1430, 1145, 917, 813, 704, 626. HRMS (ESI) calcd for C₁₅H₁₃CINO [M+H]⁺ 258.0686, found 258.0687. HPLC (Daicel Chiralcel OJ-H, *n*-hexane/*i*-PrOH = 99/1, UV = 254 nm, flow rate = 1.0 mL/min) t_{R1} =

11.685 min (minor) and $t_{R2} = 14.326$ min (major), ee = 96%. [α] 25 = -119.8 (*c* 0.16, CHCl₃).



(*3aS*, *7aS*)-2-(4-Chlorophenyl)-3a, 4, 5, 7a-tetrahydrobenzofuran-3-carbonitrile (3m): Colorless oil (50.0 mg, 97%). ¹H NMR (400 MHz, CDCl₃) δ 7.91 (dt, *J* = 8.4, 2.4 Hz, 2H), 7.91 (dt, *J* = 8.4, 2.4 Hz, 2H), 6.54–6.21 (m, 1H), 5.89–5.94 (m, 1H), 5.11–5.09 (m, 1H), 3.40 (td, *J* = 9.2, 4.8 Hz, 1H), 2.37–2.15 (m, 1H), 2.07–1.95 (m, 2H), 1.73–1.62 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 165.7, 137.3, 134.7, 128.9, 128.4, 126.8, 122.8, 117.4, 85.2, 78.8, 41.9, 23.8, 21.9. IR (KBr) (v/cm⁻¹): 3035, 2359, 1633, 1552, 1343, 996, 794, 625. HRMS (ESI) calcd for C₁₅H₁₃CINO [M+H]⁺ 258.0686, found 258.0688. HPLC (Daicel Chiralcel OJ-H, *n*-hexane/*i*-PrOH = 99/1, UV = 254 nm, flow rate = 1.0 mL/min) t_{R1} = 10.700 min (minor) and t_{R2} = 11.514 min (major), ee = 97%. [α]

 $^{25}_{\text{D}} = -149.0 \ (c \ 0.26, \text{CHCl}_3).$



(*3aS*, *7aS*)-2-(3-(Trifluoromethyl)phenyl)-3a,4,5,7a-tetrahydrobenzofuran-3-carbonitrile
(3n): Colorless oil (50.4 mg, 85%). ¹H NMR (500 MHz, CDCl₃) δ 8.24 (d, *J* = 7.5 Hz, 1H), 8.14 (s, 1H), 7.73 (d, *J* = 7.5 Hz, 1H), 7.60 (t, *J* = 8.0 Hz, 1H), 6.27–6.24 (m, 1H), 5.96–5.94 (m, 1H),

5.14 (d, J = 9.0 Hz, 1H), 3.44 (td, J = 9.0, 5.0 Hz, 1H), 2.33–2.21 (m, 1H), 2.10–1.96 (m, 2H), 1.74– 1.66 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 165.07, 134.8, 131.2 (q, J = 32.6 Hz), 130.24, 129.2 (d, J = 13.2 Hz), 127.7 (q, J = 3.6 Hz), 124.7, 123.87 (q, J = 3.9 Hz), 123.6 (d, J = 270.8 Hz), 116.9, 86.4, 79.0, 42.0, 23.7, 21.9. ¹⁹F NMR (471 MHz, CDCl₃): δ –65.0. IR (KBr) (v/cm⁻¹): 2933, 1923, 1436, 1367, 1324, 1179, 916, 695. HRMS (ESI) calcd for C₁₆H₁₃F₃NO [M+H]⁺ 292.0949, found 292.0948. HPLC (Daicel Chiralcel IC-3, *n*-hexane/*i*-PrOH = 99/1, UV = 254 nm, flow rate = 1.0 mL/min) t_{R1} = 11.770 min (minor) and t_{R2} = 12.678 min (major), ee = 95%. [α]²⁵ = -140.6 (*c* 0.20, CHCl₃).



(3aS,7aS)-2-(4-(Trifluoromethyl)phenyl)-3a,4,5,7a-tetrahydrobenzofuran-3-carbonitrile

(30): Colorless oil (48.5 mg, 83%). ¹H NMR (500 MHz, CDCl₃) δ 8.08 (d, J = 8.5 Hz, 2H), 7.71 (d, J = 8.0 Hz, 2H), 6.30–6.19 (m, 1H), 6.01–5.87 (m, 1H), 5.14 (d, J = 9.0 Hz, 1H), 3.44 (td, J = 9.0, 4.5 Hz, 1H), 2.28–2.23 (m, 1H), 2.08–2.04 (m, 2H), 1.74–1.70 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 165.1, 134.8 (dd, J = 32.5 Hz), 131.6, 127.4, 125.6 (q, J = 3.8 Hz), 123.6 (d, J = 274.7 Hz), 122.5, 116.9, 86.9, 79.0, 42.0, 23.7, 21.9. ¹⁹F NMR (471 MHz, CDCl₃): δ –63.1. IR (KBr) (v/cm⁻¹): 2933, 2202, 1991, 1324, 1128, 916, 668. HRMS (ESI) calcd for C₁₆H₁₃F₃NO [M+H]+ 292.0949, found 292.0953. HPLC (Daicel Chiralcel IC-3, *n*-hexane/*i*-PrOH = 99/1, UV = 254 nm, flow rate = 0.8 mL/min) t_{R1} = 15.512 min (minor) and t_{R2} = 16.629 min (major), ee = 96%. [α]²⁵_D = -136.7 (*c* 0.26, CHCl₃).



(3aS, 7aS)-2-(2,4-Dichlorophenyl)-3a,4,5,7a-tetrahydrobenzofuran-3-carbonitrile (3p): Colorless oil (48 mg, 82%). ¹H NMR (500 MHz, CDCl₃) δ 7.50 (d, J = 2.0 Hz, 1H), 7.47 (d, J = 8.5 Hz, 1H), 7.33 (dd, J = 8.0, 2.0 Hz, 1H), 6.28–6.24 (m, 1H), 5.92 (ddt, J = 10.0, 3.5, 2.0 Hz, 1H), 5.17 (dd, J = 8.5, 2.6 Hz, 1H), 3.46–3.37 (m, 1H), 2.33–2.22 (m, 1H), 2.11–1.95 (m, 2H), 1.79–1.67 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 166.1, 137.4, 134.8, 134.0, 131.5, 130.4, 127.2, 126.5, 122.6, 115.7, 91.0, 80.1, 41.6, 23.9, 21.9. IR (KBr) (v/cm⁻¹): 2929, 2208, 1633, 1473, 1120, 931, 794. HRMS (ESI) calcd for C₁₅H₁₂Cl₂NO [M+H]⁺ 292.0296, found 292.0300. HPLC (Daicel Chiralcel OJ-H, *n*-hexane/*i*-PrOH = 99/1, UV = 254 nm, flow rate = 1.0 mL/min) t_{R1} = 15.190 min

(minor) and $t_{R2} = 21.269 \text{ min (major)}$, ee = 93%. [α] $D^{25} = -92.1 (c \ 0.26, \text{CHCl}_3)$.



(3aS, 7aS)-2-(3,4-Difluorophenyl)-3a,4,5,7a-tetrahydrobenzofuran-3-carbonitrile (3q): Colorless oil (48.0 mg, 93%). ¹H NMR (500 MHz, CDCl₃) δ 7.85–7.70 (m, 2H), 7.31–7.19 (m, 1H), 6.29–6.20 (m, 1H), 5.96–5.87 (m, 1H), 5.15–5.07 (m, 1H), 3.41 (td, J = 9.0, 5.0 Hz, 1H), 2.31–2.18 (m, 1H), 2.10–1.95 (m, 2H), 1.74–1.65 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 164.4, 151.9 (dd, J= 229.9, 12.9 Hz), 150.0 (dd, J = 211.6, 12.9 Hz), 134.8, 125.3 (dd, J = 6.5, 3.9 Hz), 123.9 (dd, J = 6.9, 3.8 Hz), 122.6, 117. (d, J = 17.8 Hz), 117.0, 116.4 (d, J = 19.3 Hz), 85.6 (d, J = 1.7 Hz), 78.9, 42.03, 23.78, 21.93. ¹⁹F NMR (471 MHz, CDCl₃): δ –131.9 (d, J = 16.9 Hz), –135.9 (d, J = 16.9 Hz). IR (KBr) (v/cm⁻¹): 2926, 2360, 2202, 1619, 1519, 1192, 916, 734. HRMS (ESI) calcd for C₁₅H₁₂F₂NO [M+H]⁺ 260.0887, found 260.0890. HPLC (Daicel Chiralcel OJ-H, *n*-hexane/*i*-PrOH = 99/1, UV = 254 nm, flow rate = 1.0 mL/min) t_{R1} = 10.643 min (minor) and t_{R2} = 13.684 min

(major), ee = 96%. [α] $D^{25} = -163.2$ (*c* 0.23, CHCl₃).



(*3aS*, *7aS*)-2-(Naphthalen-1-yl)-3a,4,5,7a-tetrahydrobenzofuran-3-carbonitrile (3r): Colorless oil (48.6 mg, 89%). ¹H NMR (500 MHz, CDCl₃) δ 8.17 (d, *J* = 8.5 Hz, 1H), 7.98 (d, *J* = 8.0 Hz, 1H), 7.91 (d, *J* = 8.0 Hz, 1H), 7.82 (d, *J* = 7.0 Hz, 1H), 7.66–7.50 (m, 3H), 6.36–6.26 (m, 1H), 6.06–5.99 (m, 1H), 5.30 (d, *J* = 9.0 Hz, 1H), 3.52 (td, *J* = 9.0, 5.0 Hz, 1H), 2.38–2.25 (m, 1H), 2.15–1.98 (m, 2H), 1.89–1.77 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 170.0, 134.8, 133.6, 131.6, 130.5, 128.5, 128.2, 127.0, 126.4, 125.9, 125.2, 124.9, 123.0, 116.7, 89.5, 80.0, 41.4, 24.1, 21.9. IR (KBr) (v/cm⁻¹): 3420, 29224, 2203, 1507, 1386, 1349, 739. HRMS (ESI) calcd for C₁₉H₁₆NO [M+H]⁺ 274.1232, found 274.1236. HPLC (Daicel Chiralcel OJ-H, *n*-hexane/*i*-PrOH = 94/6, UV = 254 nm, flow rate = 1.0 mL/min) t_{R1} = 24.591 min (minor) and t_{R2} = 32.434 min (major), ee = 96%. [α]

 $^{25}_{\text{D}} = -56.4 \ (c \ 0.13, \text{CHCl}_3).$



(*3aS*, *7aS*)-2-(Naphthalen-2-yl)-3a,4,5,7a-tetrahydrobenzofuran-3-carbonitrile (3s): Colorless oil (51.8 mg, 95%). ¹H NMR (400 MHz, CDCl₃) δ 8.45 (s, 1H), 8.10 (dd, *J* = 8.7, 1.8 Hz, 1H), 7.94–7.85 (m, 3H), 7.64–7.48 (m, 2H), 6.27–6.23 (m, 1H), 5.99 (ddt, *J* = 12.5, 4.5, 2.5 Hz, 1H), 5.20–5.10 (m, 1H), 3.44 (td, *J* = 8.9, 4.7 Hz, 1H), 2.34–2.20 (m, 1H), 2.12–1.96 (m, 2H), 1.81–1.69 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 166.7, 134.6, 134.4, 132.6, 129.0, 128.3, 127.8, 127.7, 126.7, 125.6, 123.4, 122.9, 117.7, 85.1, 78.7, 42.1, 23.9, 22.0. IR (KBr) (v/cm⁻¹): 2929, 2198, 1922, 1435, 1193, 877, 750, 473. HRMS (ESI) calcd for C₁₉H₁₆NO [M+H]⁺ 274.1232, found 274.1231. HPLC (Daicel Chiralcel OJ-H, *n*-hexane/*i*-PrOH = 92/8, UV = 254 nm, flow rate = 1.0 mL/min) t_{R1} =

14.086 min (minor) and $t_{R2} = 24.599$ min (major), ee = 96%. [α] $D^{25} = -78.4$ (*c* 0.28, CHCl₃).



(*3aS*, *7aS*)-2-(Pyridin-2-yl)-3a, 4, 5, 7a-tetrahydrobenzofuran-3-carbonitrile (3t): Colorless oil (42.0 mg, 94%). ¹H NMR (400 MHz, CDCl₃) δ 8.80–8.71 (m, 1H), 7.84–7.73 (m, 2H), 7.40–7.32 (m, 1H), 6.30–6.17 (m, 1H), 6.00–5.91 (m, 1H), 5.22–5.13 (m, 1H), 3.43 (td, *J* = 8.8, 4.4 Hz, 1H), 2.32–2.20 (m, 1H), 2.13–1.93 (m, 2H), 1.80–1.67 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 165.2, 149.9, 147.2, 136.6, 134.7, 125.2, 122.8, 121.9, 116.9, 88.4, 79.4, 77.3, 77.0, 76.8, 42.0, 31.4, 30.2, 29.7, 23.7, 22.0. IR (KBr) (v/cm⁻¹): 3822, 2036, 2848, 1593, 1382, 1187, 855, 811, 736. HRMS (ESI) calcd for C₁₄H₁₃N₂O [M+H]⁺ 225.1028, found 225.1021. HPLC (Daicel Chiralcel OJ-H, *n*-hexane/*i*-PrOH = 95/5, UV = 254 nm, flow rate = 1.0 mL/min) t_{R1} = 21.803 min (minor) and t_{R2} =

26.914 min (major), ee = 95%. [α] $D^{25} = -172.3$ (*c* 0.27, CHCl₃).



(*3aS*, *7aS*)-2-(Pyridin-4-yl)-3a, 4, 5, 7a-tetrahydrobenzofuran-3-carbonitrile (3u): Colorless oil (43.5 mg, 94%). ¹H NMR (400 MHz, CDCl₃) δ 8.73 (dd, *J* = 4.8, 1.2 Hz, 2H), 7.79 (dd, *J* = 4.8, 1.2 Hz, 2H), 6.31–6.17 (m, 1H), 5.98–5.83 (m, 1H), 5.18–5.08 (m, 1H), 3.43 (td, *J* = 9.2, 4.8 Hz, 1H), 2.36–2.17 (m, 1H), 2.11–1.94 (m, 2H), 1.77–1.58 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 164.1, 150.3, 135.4, 134.9, 122.5, 120.5, 116.4, 88.8, 79.2, 42.1, 23.6, 21.9. IR (KBr) (v/cm⁻¹): 3085, 2359, 1654, 1482, 1159, 853, 744, 489. HRMS (ESI) calcd for C₁₄H₁₃N₂O [M+H]⁺ 225.1028, found 225.1026. HPLC (Daicel Chiralcel OD-H, *n*-hexane/*i*-PrOH = 95/5, UV = 254 nm, flow rate = 1.0

mL/min) $t_{R1} = 12.119$ min (major) and $t_{R2} = 13.792$ min (minor), ee = 97%. [α] $D^{25} = -199.7$ (*c* 0.14, CHCl₃).



(*3aS*, *7aS*)-2-(Furan-3-yl)-3a,4,5,7a-tetrahydrobenzofuran-3-carbonitrile (3v): Colorless oil (44.3 mg, 94%). ¹H NMR (500 MHz, CDCl₃) δ 7.95 (s, 1H), 7.48 (t, *J* = 2.0 Hz, 1H), 6.96 (d, *J* = 1.5 Hz, 1H), 6.28–6.17 (m, 1H), 5.90 (ddt, *J* = 10.0, 3.5, 2.0 Hz, 1H), 5.05 (d, *J* = 9.0 Hz, 1H), 3.32 (td, *J* = 9.0, 4.5 Hz, 1H), 2.28–2.14 (m, 1H), 1.99–1.98 (m, 2H), 1.66–1.58 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 162.1, 143.9, 143.8, 134.6, 122.8, 117.1, 116.0, 108.2, 84.3, 79.1, 41.2, 24.0, 22.0. IR (KBr) (v/cm⁻¹): 2848, 2200, 1646, 1456, 1367, 1170, 914, 873, 599. HRMS (ESI) calcd for C₁₃H₁₁NNaO₂ [M+H]⁺236.0687, found 236.0690. HPLC (Daicel Chiralcel OJ-H, *n*-hexane/*i*-PrOH = 99/1, UV = 254 nm, flow rate = 1.0 mL/min) t_{R1} = 12.988 min (minor) and t_{R2} = 14.658 min

(major), ee = 96%. [α] $^{25}_{D}$ = -116.5 (*c* 0.12, CHCl₃).



(*3aS*, *7aS*)-2-(Thiophen-3-yl)-3a,4,5,7a-tetrahydrobenzofuran-3-carbonitrile (3w): Yellow oil (41.0 mg, 89%). ¹H NMR (400 MHz, CDCl₃) δ 7.96 (dd, *J* = 3.2, 1.2 Hz, 1H), 7.70 (dd, *J* = 4.8, 0.8 Hz, 1H), 7.38 (dd, *J* = 5.2, 3.2 Hz, 1H), 6.24–6.19 (m, 1H), 5.94–5.90 (m, 1H), 5.08–5.06 (m, 1H), 3.36 (td, *J* = 9.2, 4.8 Hz, 1H), 2.28–2.19 (m, 1H), 2.05–1.95 (m, 2H), 1.70–1.61 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 163.1, 134.6, 130.2, 128.0, 126.5, 125.9, 122.9, 117.6, 83.7, 78.9, 41.6, 24.0, 22.0. IR (KBr) (v/cm⁻¹): 2926, 2359, 2198, 1617, 915, 792, 689. HRMS (ESI) calcd for C₁₃H₁₂NOS [M+H]⁺ 230.0640, found 230.0644. HPLC (Daicel Chiralcel OD-H, *n*-hexane/*i*-PrOH = 99/1, UV = 254 nm, flow rate = 1.0 mL/min) t_{R1} = 9.410 min (minor) and t_{R2} = 10.727 min (major), ee = 96%.

[α] $\overset{25}{D} = -123.8 (c \ 0.35, \text{CHCl}_3).$



(*3aS*, *7aS*)-2-Cyclopropyl-3a, 4, 5, 7a-tetrahydrobenzofuran-3-carbonitrile (3x): Colorless oil (30.0 mg, 79%). ¹H NMR (400 MHz, CDCl₃) δ 6.19–6.15 (m, 1H), 5.77 (ddt, *J* = 10.0, 3.6, 2.0 Hz,

1H), 4.88–4.78 (m, 1H), 3.17 (td, J = 9.2, 4.8 Hz, 1H), 2.27–2.12 (m, 1H), 2.00–1.81 (m, 3H), 1.59– 1.45 (m, 1H), 1.05–0.83 (m, 4H). ¹³C NMR (100 MHz, CDCl₃) δ 174.7, 134.5, 122.9, 117.4, 84.8, 79.1, 40.7, 24.2, 22.0, 9.7, 7.5, 7.1. IR (KBr) (v/cm⁻¹): 3394, 3036, 2848, 2205, 1593, 1219, 913, 811. HRMS (ESI) calcd for C₁₂H₁₄NO [M+H]⁺188.1075, found 188.1078. HPLC (Daicel Chiralcel OD-H, *n*-hexane/*i*-PrOH = 99/1, UV = 254 nm, flow rate = 1.0 mL/min) t_{R1} = 10.530 min (minor)

and $t_{R2} = 12.588 \text{ min (major)}$, ee = 95%. [a] $\frac{25}{10} = -185.7 (c \ 0.10, \text{CHCl}_3)$.



(3aS,7aS)-2-Ethyl-3a,4,5,7a-tetrahydrobenzofuran-3-carbonitrile (3y): Colorless oil (26.7 mg, 74%). ¹H NMR (500 MHz, CDCl₃) δ 6.23–6.16 (m, 1H), 5.85 (ddt, J = 10.0, 3.5, 2.0 Hz, 1H), 4.93 (d, J = 8.9 Hz, 1H), 3.17 (td, J = 9.0, 4.6 Hz, 1H), 2.45-2.35 (m, 2H), 2.24-2.15 (m, 1H), 2.01-1.87(m, 2H), 1.55–1.44 (m, 1H), 1.18 (t, J = 7.5 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 175.5, 134.4, 122.9, 116.8, 85.8, 79.4, 40.6, 24.3, 22.0, 21.8, 10.8. IR (KBr) (v/cm⁻¹): 3394, 2922, 2205, 1634, 1593, 1026, 987, 738. HRMS (ESI) calcd for C₁₁H₁₄NO [M+H]⁺176.1075, found 176.1078. HPLC (Daicel Chiralcel OJ-H, *n*-hexane/*i*-PrOH = 99/1, UV = 254 nm, flow rate = 1.0 mL/min) t_{R1} = 7.529

min (minor) and $t_{R2} = 8.431$ min (major), ee = 91%. [α] $^{25}_{D} = -206.9$ (c 0.11, CHCl₃).



(3aS, 7aS)-2-Phenethyl-3a, 4, 5, 7a-tetrahydrobenzofuran-3-carbonitrile (3z): Colorless oil (36.0 mg, 71%). ¹H NMR (500 MHz, CDCl₃) δ 7.34–7.28 (m, 2H), 7.27–7.17 (m, 3H), 6.20–6.17 (m, 1H), 5.85 (ddt, J = 10.0, 3.5, 2.0 Hz, 1H), 4.97–4.89 (m, 1H), 3.15 (td, J = 9.5, 4.5 Hz, 1H), 2.95– 2.85 (m, 2H), 2.78–2.64 (m, 2H), 2.14–2.08 (m, 1H), 1.95–1.82 (m, 2H), 1.50–1.38 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 173.0, 139.7, 134.5, 128.5, 128.4, 126.4, 122.9, 116.5, 87.4, 79.5, 40.6, 32.3, 29.9, 24.1, 21.9. IR (KBr) (v/cm⁻¹): 3394, 3029, 2927, 1603, 1246, 912, 699. HRMS (ESI) calcd for C₁₇H₁₈NO [M+H]⁺252.1388, found 252.1387. HPLC (Daicel Chiralcel OJ-H, n-hexane/i-PrOH = 99/1, UV = 254 nm, flow rate = 0.8 mL/min) $t_{R1} = 23.391$ min (major) and $t_{R2} = 25.118$ $^{25}_{11} = -106.1 (c \ 0.19, \text{CHCl}_3).$

min (minor), ee = 91%. $[\alpha]$



(3aS,6aS)-2-Phenyl-4,6a-dihydro-3aH-cyclopenta[b]furan-3-carbonitrile (3ba): Colorless oil (36.0 mg, 86%). ¹H NMR (500 MHz, CDCl₃) δ 7.94 (d, J = 8.0 Hz, 2H), 7.52–7.40 (m, 3H), 6.15 – 6.14 (m, 1H), 5.95–5.84 (m, 2H), 4.01 (t, J = 8.5 Hz, 1H), 2.80 (dd, J = 17.5, 7.5 Hz, 1H), 2.71 (d, J = 17.5 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 165.2, 136.0, 131.2, 128.6, 128.2, 127.1, 118.0, 92.6, 84.8, 45.6, 38.6. IR (KBr) (v/cm⁻¹): 3262, 2919, 2848, 2199, 1494, 1353, 690. HRMS (ESI) calcd for C₁₄H₁₂NO [M+H]⁺ 210.0919, found 210.0922. HPLC (Daicel Chiralcel IC-3, *n*-hexane/*i*-PrOH = 99/1, UV = 254 nm, flow rate = 1.0 mL/min) t_{R1} = 16.876 min (minor) and t_{R2} = 18.971

min (major), ee = 71%. [α] $\overset{25}{D}$ = -44.1 (*c* 0.19, CHCl₃).



(*3aS*, *8aS*)-2-Phenyl-4,5,6,8a-tetrahydro-3aH-cyclohepta[*b*]furan-3-carbonitrile (3ca): Colorless oil (44.0 mg, 91%). ¹H NMR (500 MHz, CDCl₃) δ 7.99–7.96 (m, 2H), 7.52–7.41 (m, 3H), 5.89–5.74 (m, 2H), 5.57 (d, *J* = 10.0 Hz, 1H), 3.38 (td, *J* = 10.5, 3.0 Hz, 1H), 2.31–2.11 (m, 2H), 1.97–1.85 (m, 1H), 1.85–1.77 (m, 1H), 1.70–1.62 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 165.3, 131.2, 129.6, 128.6, 128.0, 127.1, 126.7, 117.7, 85.2, 84.6, 45.9, 26.9, 26.4, 21.3. IR (KBr) (v/cm⁻¹): 3422, 2926, 2360, 2202, 1701, 1448, 1075, 691. HRMS (ESI) calcd for C₁₆H₁₆NO [M+H]⁺ 238.1232, found 238.1230. HPLC (Daicel Chiralcel OJ-H, *n*-hexane/*i*-PrOH = 99/1, UV = 254 nm,

flow rate = 1.0 mL/min) t_{R1} = 7.561 min (minor) and t_{R2} = 9.307 min (major), ee = 79%. [α] $_{D}^{25}$ = -26.8 (*c* 0.19, CHCl₃).

5. Transformations

5.1 Procedure for the gram-scale synthesis of 3a



A flame-dried Schlenk tube equipped with a magnetic stirring bar, was charged with a mixture of $[Pd(\eta^3-C_3H_5)Cl]_2$ (64.1 mg, 2.5 mol%) and L1 (178.5 mg, 3.0 mol%). After being evacuated and backfilled with nitrogen three times, 1,4-dioxane (20 mL) was added to the Schlenk tube and the mixture was stirred at room temperature under a N₂ atmosphere for 1 h. Allylic biscarbonates **1a** (8.4 mmol, 1.2 equiv) was added via a syringe followed by addition of benzoyl acetonitrile **2a** (7.0 mmol) under a N₂ atmosphere. The reaction mixture was allowed to stir under a N₂ atmosphere at room temperature for 24 h. 1,4-dioxane was evaporated in vacuo and the residue was purified by flash silica gel column chromatography (PE/EA = 20/1) to give product **3a**.

5.2 Procedure for synthesis of 4 and characterization data^[13]



(*3aS*, *7aS*)-2-phenyl-3a, 4, 5, 7a-tetrahydrobenzofuran-3-carboxamide (4): To a glass tube were added diacetoxypalladium (0.02 mmol, 4.6 mg), triphenylphosphine (0.04 mmol, 10.6 mg), and EtOH / H₂O (1.6 mL / 0.4 mL). Then, **3a** (22.3 mg, 0.1 mmol), and acetaldehyde oxime (0.8 mmol, 47.2 mg) were added and the mixture was stirred at 75 °C. After 12 hours, the mixture was cooled down to room temperature and then directly subjected to silica gel column chromatography (EA/PE =1/3 to EA/PE =1/1) to give pure product **4** as white gummy oil (15.2 mg, 63%). ¹H NMR (500 MHz, CDCl₃) δ 7.64–7.57 (m, 2H), 7.48–7.38 (m, 3H), 6.28–6.19 (m, 1H), 6.00 (d, *J* = 10.0 Hz, 1H), 5.69 (brs, 1H), 5.25 (brs, 1H), 4.91 (d, *J* = 8.5 Hz, 1H), 3.34–3.18 (m, 1H), 2.27–2.09 (m, 2H), 2.03–1.92 (m, 1H), 1.53 (ddd, *J* = 15.0, 11.0, 3.5 Hz, 1H).¹³C NMR (100 MHz, CDCl₃) δ 167.4, 160.8, 134.6, 130.5, 130.3, 129.0, 128.7, 123.1, 11.3, 77.8, 42.3, 24.9, 23.2. IR (KBr) (v/cm⁻¹): 3393, 3057, 2925, 2359, 1654, 1592, 1437, 1264, 1180, 1119, 694, 540. HRMS (ESI) calcd for C₁₅H₁₅NNaO₂ [M+Na]⁺ 264.1000, found 264.1003. HPLC (Daicel Chiralcel OJ-H, *n*-hexane/*i*-PrOH = 90/10, UV = 254 nm, flow rate = 1.0 mL/min) t_{R1} = 8.253 min (major) and t_{R2} = 14.790

min (minor), ee = 95%. [α] $^{25}_{D}$ = -107.8 (*c* 0.10, CHCl₃).

5.3 Procedure for synthesis of 5 and characterization data^[14]



4-Methyl-*N***-(((***3aS*, *7aS*)**-2-phenyl-3a**, **4**, **5**, **7a-tetrahydrobenzofuran-3-yl)methyl)benzenesulfon amide (5):** Under N₂ atmosphere, **3a** (22.3 mg, 0.1 mmol) in dry THF (0.5 mL) was added dropwise

to a stirred suspension of lithium aluminum hydride (1 M in THF, 0.2 mL) in dry THF (0.5 mL) at 0 °C. The resulting solution was then allowed to warm slowly to room temperature and stirred for ca. 3 h, and the mixture was quenched by the addition of a 10% sodium hydroxide solution (2.0 mL). The mixture was then filtered through Celite, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to give the crude primary amine as a colorless oil, which was used in the next step without further purification. TsCl (23.0 mg, 0.1 mmol) in dry CH₂Cl₂ (0.5 mL) was added to a solution of crude primary amine and Et₃N (28 µL, 0.2 mmol) in dry CH₂Cl₂ (1.0 mL) at 0 °C under an atmosphere of N_2 . The resulting solution was then allowed to warm slowly to room temperature and stirred for 24 h. The residue was purified by flash silicagel column chromatography (PE:EA = 3:1) to afford the desired product 5 as a colorless oil (32.5 mg, 89% yield for two steps). ¹H NMR (500 MHz, CDCl₃) δ 7.77 (d, J = 8.5 Hz, 2H), 7.32 –7.25 (m, 7H), 6.19–6.09 (m, 1H), 5.96-5.94 (m, 1H), 4.73-4.61 (m, 2H), 3.92 (dd, J = 13.5, 4.5 Hz, 1H), 3.78 (dd, J = 13.5, 7.0 Hz, 1H), 2.94–2.85 (m, 1H), 2.50–2.42 (m, 3H), 2.12–2.04 (m, 1H), 1.92–1.78 (m, 2H), 1.34–1.30 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 153.1, 143.5, 136.6, 133.2, 130.6, 129.7, 128.8, 128.3, 127.3, 127.2, 124.2, 75.8, 42.2, 39.5, 24.0, 22.9, 21.5. IR (KBr) (v/cm⁻¹): 3775, 3405, 2927, 2359, 2341, 1493, 1383, 1350, 1060, 935, 740, 698. HRMS (ESI) calcd for C₂₂H₂₄NO₃S [M+H]⁺ 382.1471, found 382.1474. HPLC (Daicel Chiralcel IC-3, *n*-hexane/*i*-PrOH = 90/10, UV = 210 nm, flow rate = 0.8 mL/min) t_{R1} = 44.865 min (major) and t_{R2} = 48.359 min (minor), ee = 98%. $[\alpha]_{T1}^{25}$ = -54.7 (c 0.35, CHCl₃).

5.4 Procedure for synthesis of 6 and characterization data^[15]



(2*R*,3*S*,3*aS*,7*aS*)-2-Phenyl-2,3,3a,4,5,7a-hexahydrobenzofuran-3-carbonitrile (6): Under N₂ atmosphere, **3a** (22.3 mg, 0.1 mmol) and BF₃·Et₂O (28 µL, 0.22 mol)were added to a solution of Et₃SiH (32 µL, 0.2 mmol) in anhydrous DCM (2 mL) and the reaction mixture was stirred at -20 °C for 20 h. The mixture was quenched with 10% NaHCO₃ solution and the mixture was extracted with DCM (6 mL × 3). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash silicagel column chromatography (PE:EA = 20:1) to afford the desired product **6** as a colorless oil (21 mg, 93%). ¹H NMR (500 MHz, CDCl₃) δ 7.46 (d, *J* = 8.0 Hz, 2H), 7.44–7.40 (m, 2H), 7.37–7.34 (m, 1H), 6.20–6.11 (m, 1H), 5.96 (dd, *J* = 9.5, 1.0 Hz, 1H), 5.20 (d, *J* = 9.5 Hz, 1H), 4.63 (s, 1H), 3.22 (dd, *J* = 9.0, 1.5 Hz, 1H), 2.70–2.64 (m, 1H), 2.37–2.33 (m, 1H), 2.14–2.02 (m, 2H), 1.75–1.63 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 139.7, 132.6, 128.8, 128.5, 125.4, 117.6, 80.7, 75.0, 43.5, 39.9, 23.5, 21.6. IR (KBr) (v/cm⁻¹):

3451, 3281, 2924, 1598, 1327, 1093, 1037, 814, 699, 569, 550. HRMS (ESI) calcd for $C_{15}H_{16}NO$ [M+H]⁺ 226.1226, found 226.1228. HPLC (Daicel Chiralcel OD-H, *n*-hexane/*i*-PrOH = 99/1, UV = 210 nm, flow rate = 1.0 mL/min) t_{R1} = 14.492 min (minor) and t_{R2} = 15.396 min (major), ee = 97%. [α]²⁵_D = -67.1 (*c* 0.24, CHCl₃).

5.5 Procedure for synthesis of 7 and characterization data



(*2R*,*3S*,*3aS*,*7aS*)-2-Phenyloctahydrobenzofuran-3-carbonitrile (7): **3**a (22.3 mg, 0.1 mmol) was treated with Pd/C (10 mol%) in MeOH, the mixture was stirred under H₂ (40 bar) at r.t. in a stainless-steel autoclave for 24 h. Then Pd/C was filtered and the organic layer was concentrated under reduced pressure. The residue was purified by flash silicagel column chromatography (PE:EA = 10:1) to afford the desired product 7 as a white solid (20.0 mg, 90%). Mp: 89–90 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.44–7.38 (m, 4H), 7.35–7.31 (m, 1H), 5.12 (d, J = 9.6 Hz, 1H), 4.01 (dd, J = 6.6, 3.2 Hz, 1H), 3.63 (dd, J = 9.6, 7.3 Hz, 1H), 2.37 (ddd, J = 11.2, 6.6, 4.2 Hz, 1H), 2.25–2.19 (m, 1H), 1.86–1.77 (m, 2H), 1.73–1.65 (m, 2H), 1.59 (dd, J = 6.6, 2.4 Hz, 1H), 1.48 (ddd, J = 25.2, 12.6, 3.6 Hz, 1H), 1.28–1.23 (m, 1H). ¹³C NMR (150 MHz, CDCl₃) δ 138.2, 128.5, 128.4, 126.3, 117.5, 79.7, 77.6, 41.5, 40.2, 27.7, 26.0, 24.2, 20.3. IR (KBr) (v/cm⁻¹):2925, 1600, 1395, 771, 760, 427. HRMS (ESI) calcd for C₂₂H₂₄NO₃S [M+NH₄]⁺ 245.1648, found 245.1649. HPLC (Daicel Chiralcel AS-H, *n*-hexane/*i*-PrOH = 90/10, UV = 210 nm, flow rate = 1.0 mL/min) t_{R1} = 10.658 min (major) and t_{R2} = 13.604 min (minor), ee = 94%. [α]^D²⁵ = -46.3 (*c* 0.11, CHCl₃).

5.6 Procedure for synthesis of 8 and characterization data^[14]



((3*R*,3*a*S,7*a*S)-2,2-Diphenyl-2,3,3*a*,4,5,7*a*-hexahydrobenzofuran-3-yl)(phenyl)methanone (8): Phenylmagnesium bromide (0.1 mL, 0.3 mmol; 3M solution in tetrahydrofuran) was added dropwise to a stirred solution of 3a (22.3 mg, 0.1 mmol) in toluene (2.0 mL) at room temperature under an atmosphere of N₂ and the resulting yellow solution heated to 110 °C for 12 hours. The mixture was then allowed to cool to room temperature and quenched with water (2 mL). A solution of acetic acid, tetrahydrofuran and water (4:1:1; 10 mL) was then added and the resulting biphasic mixture stirred vigorously for ca. 4 hours. The mixture was then partitioned between ethyl acetate (10 mL) and 2M sodium hydroxide solution (20 mL). The organic layers were combined, washed

with a saturated aqueous sodium bicarbonate solution, saturated aqueous sodium chloride solution, dried (anhyd. MgSO₄), filtered and concentrated in vacuo to afford the crude product. Purification by flash column chromatography (PE:EA = 10:1) afforded the aryl ketone (19.7 mg, 52%) as a colorless oil. ¹H NMR (600 MHz, CDCl₃) δ ¹H NMR (600 MHz, CDCl₃) δ 7.44–7.38 (m, 4H), 7.35–7.31 (m, 1H), 5.12 (d, *J* = 9.6 Hz, 1H), 4.01 (dd, *J* = 6.6, 3.0 Hz, 1H), 3.63 (dd, *J* = 9.6, 7.2 Hz, 1H), 2.37 (ddd, *J* = 11.4, 6.6, 4.2 Hz, 1H), 2.25–2.19 (m, 1H), 1.86–1.77 (m, 2H), 1.73–1.65 (m, 2H), 1.59 (dd, *J* = 6.6, 2.4 Hz, 1H), 1.48 (ddd, *J* = 25.2, 12.0, 3.6 Hz, 1H), 1.28–1.23 (m, 1H). ¹³C NMR (150 MHz, CDCl₃) δ 196.4, 144.2, 137.3, 136.4, 133.5, 133.2, 128.8, 128.7, 128.6, 128.5, 128.4, 128.3, 126.7, 58.4, 44.9, 42.8, 29.7, 23.8, 21.4. IR (KBr) (v/cm⁻¹): 3446, 2830, 1631, 1362, 1076, 786. HRMS (ESI) calcd for C₂₂H₂₄NO₃S [M+H]⁺ 381.1849, found 381.1847. HPLC (Daicel Chiralcel OD-H, *n*-hexane/*i*-PrOH = 92/8, UV = 254 nm, flow rate = 1.0 mL/min) t_{R1} = 4.759 min (major) and t_{R2} = 5.271 min (minor), ee = 96%. [α]²⁵/_D = 10.8 (*c* 0.5, CHCl₃).

6. NMR Spectra















210 200 190 180 170 160 150 140 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 fl (ppm)














S36



-187.093 136.147 136.147 131.632 132.276 131.632 129.749 129.532 129.187 129.187 129.187 129.187 129.187 129.187 114.004 114.004



210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 fl(gpm)





S39





















$\begin{array}{c} 7.530\\ 7.515\\ 7.515\\ 7.515\\ 7.515\\ 7.515\\ 7.515\\ 7.266\\ 7.266\\ 7.266\\ 7.255\\ 6.261\\ 6.250\\ 6.250\\ 6.250\\ 6.250\\ 6.250\\ 6.261\\ 6.261\\ 6.260\\ 5.916\\ 5.916\\ 5.916\\ 5.916\\ 5.916\\ 5.916\\ 5.916\\ 5.916\\ 5.916\\ 5.926\\ 5.$













$\begin{array}{c} 75.89\\ 7.573\\ 7.477\\ 7.477\\ 7.477\\ 7.482\\ 7.355\\ 7.355\\ 7.355\\ 7.335\\ 7.335\\ 7.030\\ 7.030\\ 7.030\\ 7.030\\ 7.030\\ 7.030\\ 7.030\\ 7.030\\ 6.225\\ 6.221\\ 6.225\\ 6.2222\\ 6.2222\\$





$\begin{array}{c} 7.953\\ 7.946\\ 7.929\\ 6.941\\ 7.929\\ 6.9559\\ 6.9559\\ 6.942\\ 6.942\\ 6.942\\ 6.942\\ 6.943\\ 6.229\\ 6.215\\ 6.933\\ 6.223\\ 6.233\\ 6.223\\ 6.233\\$













S51





210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 60 40 30 20 10 0 -10 fl (ppm)







7,996 7,991 7,979 7,979 7,979 7,979 7,966 7,966 6,244 6,230 6,244 6,230 6,244 6,233 6,5915 5,5935 5,5915 5,





$\begin{array}{c} 7.912\\ 7.858\\ 7.441\\ 7.391\\ 7.391\\ 7.391\\ 7.391\\ 7.391\\ 7.391\\ 7.391\\ 7.391\\ 7.391\\ 7.391\\ 7.391\\ 7.391\\ 6.242\\ 6.207\\ 5.900\\ 5.900\\ 5.900\\ 5.900\\ 5.900\\ 5.900\\ 5.900\\ 5.900\\ 7.2013\\ 3.411\\ 5.910\\ 5.900\\ 5.900\\ 7.2013\\ 7.2013\\ 7.2013\\ 7.2013\\ 7.2013\\ 7.2013\\ 7.2013\\ 7.2013\\ 7.2013\\ 7.2013\\ 7.2014\\ 7.2013\\ 7.2013\\ 7.2014\\ 7.2013\\ 7.2013\\ 7.2014\\ 7.2014\\ 7.2014\\ 7.2013\\ 7.2014\\ 7.2013\\ 7.2014\\ 7.2013\\ 7.2014\\ 7.20$











8.220 8.097 7.707 7.707 7.768 7.768 7.768 7.768 7.7580 6.217 6.230 6.217 6.230 6.217 6.233 6.195 6.217 6.233 6.217 6.233 6.217 7.560 6.233 6.217 7.560 6.233 6.217 7.560 6.233 6.217 7.560 6.233 6.217 7.560 6.233 7.590 6.233 7.590 6.217 7.500 6.217 7.500 6.233 7.590 6.217 7.500 6.233 7.590 6.217 7.500 6.233 7.590 6.217 7.500 6.231 7.500 6.231 7.500 6.231 7.500 6.231 7.500 6.231 7.500 6.231 7.500 6.231 7.500 6.231 7.500 6.231 7.500 6.231 7.500 6.231 7.500 6.231 7.500 6.231 7.500 6.231 7.500 6.231 7.500 6.232 7.500 6.201 7.500 6.201 7.500 6.201 7.500 6.201 7.500 6.201 7.500 6.201 7.500 6.201 7.500 6.201 7.500 6.201 7.500 6.201 7.500 6.201 7.500 6.201 7.500 6.201 7.500 6.201 7.500 7.500 7.500 7.500 7.500 7.500 7.500 7.500 7.500 7.500 7.500 7.500 7.500 7.500 7.500 7.500 7.500 7.500 7.500 7.202











-165.160 134.810 132.843 132.843 132.843 132.582 132.422 127.402 127.402 127.605 125.552 12













$\begin{array}{r} 8.130\\ 8.110\\ 7.796\\ 7.796\\ 7.779\\ 7.779\\ 7.779\\ 7.773\\ 7.557\\ 7.557\\ 7.573\\ 7.573\\ 7.557\\ 7.573\\ 7.553\\ 7.554\\ 7.554\\ 7.554\\ 7.554\\ 7.554\\ 7.538\\ 7.5596\\ 7.538\\ 7.5596\\ 7.5990\\ 7.5990\\ 7.5990\\ 7.5990\\ 7.5990\\ 7.5990\\ 7.5900\\ 7.5900\\ 7.5900\\ 7.5900\\ 7.5900\\ 7.5900\\ 7.5900\\ 7.5900\\ 7.5900\\ 7.5900\\ 7.5900\\ 7.5900\\ 7.5900\\ 7.5900\\ 7.200$















8.77 8.77 8.77 8.77 8.77 8.77 8.77 7.78 8.77 7.78 8.77 7.78 7.778 6.241 6.241 6.241 6.241 5.934 5.933 5.934 5.933 5.945 5.934 5.933 5.934 5.933 5.934 5.933 5.934 5.933 5.934 5.933 5.934 5.933 5.934 5.933 5.934 5.934 5.934 5.933 5.934 <







77.945 77.477 77.473 6.0961 6.0961 6.0230 6.0230 6.0230 6.0230 6.0230 6.0230 6.0230 6.0230 6.0230 6.0230 6.0230 5.035 5.5891 5.5891 5.5891 5.5891 5.5893 5.5035 5.5035 5.5035 5.5035 5.5035 5.50





$\begin{array}{c} 7.962\\ 7.955\\ 7.956\\ 7.708\\ 7.708\\ 7.795\\ 7.795\\ 7.795\\ 7.795\\ 7.791\\ 7.378\\ 7.378\\ 7.378\\ 7.378\\ 7.378\\ 7.378\\ 7.378\\ 7.378\\ 7.378\\ 7.378\\ 7.378\\ 7.593\\ 7.$













7.326 7.312 7.297 7.297 7.249 7.249 7.249 7.249 7.249 7.220 6.176 6.176 6.176 6.176 5.863 7.229 7.2010











$\begin{array}{c} 7.985\\ 7.973\\ 7.973\\ 7.973\\ 7.479\\ 7.475\\ 7.477\\ 7.477\\ 7.477\\ 7.477\\ 7.477\\ 7.477\\ 7.477\\ 7.477\\ 7.477\\ 7.477\\ 7.475\\ 7.477\\ 7.475\\ 7.482\\ 7.475\\ 7.482\\ 7.$


























$^{\circ}$ $^{\circ}$





NOESY 8

The relative stereochemistry of this compound was corroborated by NOE experiments (as indicated on the compound structure and the figure).



7. HPLC Data



Racemate:











125-检测器A 254nm 10.955 13.913 100-75-50-25-0-5 10 15 20 25 Ò min















Peak 1	14.148	1.791	96% ee
Peak 2	15.523	98.209	

















Chiral:



S85





























Chiral:

Peak 2

11.514



98.310



































Chiral:

Peak 2

24.599



97.986



























































Chiral:

Peak 2

14.790



2.421







	Retention Time (min)	Area (%)	
Peak 1	44.865	98.793	98% ee
Peak 2	48.359	1.207	


Racemate:



Chiral:

Peak 2

15.396



98.672



Racemate:



Chiral:





Racemate:



Chiral:



	Retention Time (mm)	Alea (%)	
Peak 1	4.759	98.074	96% ee
Peak 2	5.271	1.926	

S110

8. X-ray Crystal Structure Analysis

X-Ray Crystallography Data for **3f** (CCDC 1940926): A colorless crystal suitable for X-ray crystallography was obtained from a *n*-hexane/dichloromethane solution at room temperature under air.



Bond precision:	C-C = 0.0059 A	Wavelength=1.54178	
Cell:	a=4.6461(6) alpha=90	b=11.4107(16) beta=90	c=24.622(3) gamma=90
Temperature:	293 K		
	Calculated	Reporte	d
Volume	1305.3(3)	1305.3(3)
Space group	P 21 21 21	P 21 21 21	
Hall group	P 2ac 2ab	P 2ac 2ab	
Moiety formula	C16 H15 N 02	C16 H15 N 02	
Sum formula	C16 H15 N O2	C16 H15 N O2	
Mr	253.29	253.29	
Dx,g cm-3	1.289	1.289	
Z	4	4	
Mu (mm-1)	0.683	0.683	
F000	536.0	536.0	
F000'	537.60		
h,k,lmax	5,13,28	5,13,28	
Nref	2164[1310]	2155	
Tmin, Tmax	0.872,0.903	0.519,0.753	
Tmin'	0.872		
Correction metho AbsCorr = ?	od= # Reported T	Limits: Tmin=0.51	9 Tmax=0.753
Data completenes	ss= 1.65/1.00	Theta $(max) = 63$.	758
R(reflections) =	0.0562(1913)	wR2(reflections)= 0.1632(2155)
S = 1.158	Npar=	174	

X-Ray Crystallography Data for 7 (CCDC 1945273): A colorless crystal suitable for X-ray crystallography was obtained from a *n*-hexane/dichloromethane solution at room temperature under air.



Bond precision:	C-C = 0.0039 A	Wavelength=1.54178	
Cell:	a=5.9300(1)	b=8.7765(2)	c=24.7421(6)
	alpha=90	beta=90	gamma=90
Temperature:	297 K		
	Calculated	Report	ted
Volume	1287.69(5)	1287.6	59(5)
Space group	P 21 21 21	P 21 21 21	
Hall group	P 2ac 2ab	P 2ac 2ab	
Moiety formula	C15 H17 N O	C15 H1	IT NO
Sum formula	C15 H17 N O	C15 H1	17 N O
Mr	227.30	227.29	
Dx,g cm-3	1.172	1.172	
Z	4	4	
Mu (mm-1)	0.571	0.571	
F000	488.0	488.0	
F000'	489.33		
h,k,lmax	7,10,29	7,10,2	29
Nref	2364[1408]	2353	
Tmin, Tmax	0.892,0.913	0.679,	0.753
Tmin'	0.892		
Correction meth AbsCorr = ?	od= # Reported T 1	Limits: Tmin=0.6	79 Tmax=0.753
Data completene	88= 1.67/1.00	Theta(max)= 68	8.308
R(reflections)=	0.0387(2161)	wR2(reflection	ns)= 0.1079(2353)
S = 1.046	Npar=	154	

9. References

- 1. J. X. Shen, D, J. Yang, Y. X. Liu and R. H. Liu, Org. Lett. 2014, 16, 350.
- 2. H. Vzquez-Villa, S. Reber and M. A. Ariger, Carreira, E. M. Angew. Chem. Int. Ed. 2011, 50, 8979.
- 3. A. D. Mamuye, L. Castoldi and V. Pace, Org. Biomol. Chem. 2015, 13, 1969.
- 4. L. Joubran, W. R. Jackson, E. M. Campi and B. Jarrott, Aust. J. Chem. 2003, 56, 597.
- 5. S. Y. Lee, T. Kim, B. H. Lee and K. Y. Yia, *Bioogr. Med. Chem. Lett.* 2007, 17, 1291.
- 6. G. Rai, K. R. Brimacombe and B. T. Mott, J. Med. Chem. 2017, 60, 9184.
- 7. R. Zanaletti, L. Bettinetti, C. Castaldo and M. Valacchi, J. Med. Chem. 2012, 55, 4806.
- 8. S. Kamila, D. M. Zhu, E. R. Biehl and L. Hua, Org. Lett. 2006, 8, 4429.
- 9. J. Zhou, X. H. Zhu and Y. Q. Wan, Eur. J. Org. Chem. 2017, 16, 2317.
- 10. T. Nagata, H. Matsubara, K. Kiyokawa and S. Minakata, Org. Lett. 2017, 19, 4672.
- 11. Q. An, D. Liu, J. Shen, Y. Liu and W. Zhang, Org. Lett. 2017, 19, 238.
- (a) J. Chiang and S. Bauer, *J. Am. Chem. Soc.* 1969, **91**, 1898; (b) J. Fiaud and L. Aribi-Zouioueche, *J. Chem. Soc., Chem. Commun.* 1986, 390; (c) H.Yoshizaki, H. Satoh, Y. Sato, S. Nukui, M. Shibasaki and M. Mori, *J. Org. Chem.* 1995, **60**, 2016.
- 13. J. Feng, X. Yuan, W. Luo, L. Lin, X. Liu and X. Feng, Chem. Eur. J. 2016, 22, 15650.
- 14. B. Turnbull and P. Evans, J. Am. Chem. Soc. 2015, 137, 6156.
- 15. Q. An, J. Shen, N. Butt, D. Liu, Y. Liu and W. Zhang, Adv. Synth. Catal. 2015, 357, 3627.